Figure 3.

SC1 cures mice bearing RMA-S lymphoma. (A) C57BL/6 mice (n = 6 per group) were injected with 10⁶ RMA-S cells s. c. into the flank. Mice were treated with 2 mg/kg R848, 10 mg/kg SC1 or vehicle s. c. into the contralateral flank (each n = 5) every 5th day beginning on day 0 through day 50. (B) Tumor growth and survival of C57BL/6 wild-type mice bearing s. c. RMA-S tumors. Results are representative of three independent experiments. (C) TLR7-deficient mice (n = 8 per group) were injected with 10⁶ RMA-S cells s. c. in the flank. Contralateral s. c. treatment with 10 mg/kg SC1 or vehicle was administered every 5th day from day 0. Tumor growth over time is shown. (D) IFNAR-deficient mice (n = 11 per group) were injected with 10⁶ RMA-S tumor cells s. c. into the flank. Contralateral s.c. treatment with 10 mg/kg SC1 or vehicle was administered every 5th day from day 0. Tumor growth over time is displayed. C and D show results of two independent experiments. Statistical significance was analyzed by two-way Anova with correction for multiple testing. p values < 0.05 were considered significant.